These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 15887675

  • 1. [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
    März W.
    MMW Fortschr Med; 2005 Apr 07; 147(14):14. PubMed ID: 15887675
    [No Abstract] [Full Text] [Related]

  • 2. [Diabetic dyslipidemia: which target levels and treatment options exist for diabetics?].
    Broedl UC, Lehrke M, Parhofer KG.
    MMW Fortschr Med; 2008 Jun 19; 150(25):41-3. PubMed ID: 18705054
    [No Abstract] [Full Text] [Related]

  • 3. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA.
    Atheroscler Suppl; 2005 Sep 19; 6(3):21-7. PubMed ID: 16054442
    [Abstract] [Full Text] [Related]

  • 4. Choice of lipid-regulating drugs.
    Med Lett Drugs Ther; 2001 May 28; 43(1105):43-8. PubMed ID: 11378632
    [No Abstract] [Full Text] [Related]

  • 5. [Dyslipidemia in diabetes mellitus].
    Niemeijer-Kanters SD, Banga JD, Erkelens DW.
    Ned Tijdschr Geneeskd; 2001 Apr 21; 145(16):769-74. PubMed ID: 11346913
    [Abstract] [Full Text] [Related]

  • 6. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J.
    Diabetes Obes Metab; 2007 Sep 21; 9(5):609-16. PubMed ID: 17697054
    [Abstract] [Full Text] [Related]

  • 7. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH.
    Am J Cardiol; 2008 Dec 22; 102(12A):41L-47L. PubMed ID: 19084089
    [Abstract] [Full Text] [Related]

  • 8. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    Kastelein JJ.
    Am J Cardiol; 2005 Nov 07; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF.
    Arterioscler Thromb Vasc Biol; 2008 Jun 07; 28(6):1172-8. PubMed ID: 18356553
    [Abstract] [Full Text] [Related]

  • 10. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.
    Clin Ther; 2007 Aug 07; 29(8):1671-81. PubMed ID: 17919548
    [Abstract] [Full Text] [Related]

  • 11. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
    Toth PP.
    Am J Cardiol; 2005 Nov 07; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015
    [Abstract] [Full Text] [Related]

  • 12. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M.
    Dtsch Med Wochenschr; 2009 May 07; 134(20):1067-73. PubMed ID: 19421932
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy in the management of mixed dyslipidaemia.
    Cannon CP.
    J Intern Med; 2008 Apr 07; 263(4):353-65. PubMed ID: 18324928
    [Abstract] [Full Text] [Related]

  • 14. Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.
    Jaffer FA.
    J Am Coll Cardiol; 2009 Nov 03; 54(19):1795-6. PubMed ID: 19874993
    [No Abstract] [Full Text] [Related]

  • 15. [Treatment of dyslipoproteinemia risk factor. Lipid therapy must become multidimensional].
    MMW Fortschr Med; 2008 Jun 26; 150(26-27):52-3. PubMed ID: 18681233
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of high-risk older persons with lipid-lowering drug therapy.
    Aronow WS.
    Am J Ther; 2008 Jun 26; 15(2):102-7. PubMed ID: 18356628
    [Abstract] [Full Text] [Related]

  • 17. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.
    J Am Coll Cardiol; 2008 Apr 22; 51(16):1564-72. PubMed ID: 18420099
    [Abstract] [Full Text] [Related]

  • 18. [New drug against lipid disorders. HDL level rises 30%].
    MMW Fortschr Med; 2003 Sep 25; 145(39):51. PubMed ID: 14649076
    [No Abstract] [Full Text] [Related]

  • 19. [Total cardiovascular risk. When is a medication prophylaxis meaningful].
    Einecke D.
    MMW Fortschr Med; 2003 Oct 30; 145(44):6-8. PubMed ID: 14655495
    [No Abstract] [Full Text] [Related]

  • 20. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P.
    Am J Manag Care; 2009 Mar 30; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.